The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2022 | The promise of targeted combination therapies in CLL & their impact on immune function
Clare Sun, MD, National Institutes of Health, Bethesda, MD, shares her excitement for clinical trials evaluating targeted therapy combinations in chronic lymphocytic leukemia (CLL), highlighting the importance of investigating the impact these therapies may have on the immune system. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: Genmab
